FDA
-
-
-
-
-
-
-
Harmony Biosciences (HRMY) Receives U.S. Food And Drug Administration Orphan Drug Designation For Pitolisant In Prader-willi Syndrome
-
-
-
-
-
-
-
Harmony Biosciences Reports Strong Third Quarter 2023 Financial Results
-
-
-
-
-
-
-
HARMONY BIOSCIENCES PRESENTS NEW SECONDARY OUTCOME DATA FROM PHASE 2 SIGNAL DETECTION STUDY IN PATIENTS WITH PRADER-WILLI SYNDROME
-
-
-
-
-
-
-
HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.
-
-
-
-
-
-
-
HARMONY BIOSCIENCES ANNOUNCES POSITIVE PHASE 2 SIGNAL DETECTION STUDY EVALUATING PITOLISANT FOR EXCESSIVE DAYTIME SLEEPINESS IN PRADER-WILLI SYNDROME AT SLEEP 2023
-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Is Investigating LivePerson, and Harmony and Encourages Investors to Contact the Firm
-
-
-
-
-
-
-
Harmony Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
-
251,761 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All